The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Keytruda was produced by Merck & Co..
PD-1 inhibitor Keytruda (pembrolizumab) following the new agreement.
The phase 3 KEYNOTE-590 trial evaluated Keytruda (pembrolizumab) in combination with chemotherapy in first-line oesophageal cancer. ... Currently, Bristol Myers Squibb’s rival checkpoint inhibitor Opdivo (nivolumab) is Keytruda’s only potential
Merck &Co’s checkpoint inhibitor Keytruda (pembrolizumab) currently holds much of the NSCLC market, although the drug failed to show benefit in SCLC when added to chemotherapy.
Tyvyt’s major rival is Merck &Co’s Keytruda (pembrolizumab), which holds approvals across a range of NSCLC indications. ... Keytruda has quickly been established as the new standard of care in NSCLC, after data from the KEYNOTE-189 study found that
TNBC is an important niche for Roche’s checkpoint inhibitor, in a class that is otherwise dominated by Merck &Co’s PD-1 inhibitor Keytruda (pembrolizumab). ... Despite the fail in TNBC, Keytruda is far ahead of its rivals in terms of revenues,
[ Previous 5 results ] 3 4 5 6 7 8 9 10 11 12 [ Next 5 results ]
up to your ears in it? some pressure is helpful but too much of the wrong sort quickly takes its...